Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Immunology, Immunotherapy : CII|November 23, 2018
An alphavirus-based therapeutic cancer vaccine: from design to clinical trialAmrita Singh, Georgia Koutsoumpli, Stephanie van de Wall, et al.
Vaccine|July 4, 2024
An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccinesGeorgia Koutsoumpli, Neringa Stasiukonyte, Baukje Nynke Hoogeboom, et al.
Therapeutic Advances in Vaccines and Immunotherapy|October 18, 2019
Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?Georgia Koutsoumpli, Peng Peng Ip, Ilona Schepel, et al.
Vaccines|November 27, 2019
A PBMC-Based System to Assess Human T Cell Responses to Influenza Vaccine Candidates In VitroGabriela Tapia-Calle, Philip A Born, Georgia Koutsoumpli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2017
TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory RecallMarcin Cebula, Mathias Riehn, Upneet Hillebrand, et al.
Biomedicines|May 25, 2024
Hotspot DNA Methyltransferase 3A (<i>DNMT3A</i>) and Isocitrate Dehydrogenase 1 and 2 (<i>IDH1/2</i>) Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for ImmunotherapyNadine E Struckman, Rob C M de Jong, M Willy Honders, et al.
Molecular Therapy. Methods & Clinical Development|March 22, 2024
Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapyIsabella Elias Yonezawa Ogusuku, Vera Herbel, Simon Lennartz, et al.
Leukemia|December 13, 2025
A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemiaNadine E Struckman, Georgia Koutsoumpli, Rob C M de Jong, et al.
Blood|March 1, 2024
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigensKyra J Fuchs, Marian van de Meent, M Willy Honders, et al.
Cancers|November 13, 2021
An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AMLDyantha I van der Lee, Georgia Koutsoumpli, Rogier M Reijmers, et al.
Pageof 1